LIGHTNING RELEASES 03/21/14 –WASHINGTON, D.C. – Noting the critical role routine clinical lab tests play in the diagnosis of Chronic Kidney Disease (CKD) and many other diseases – such as diabetes and high blood pressure – that may lead to or develop following a CKD diagnosis, the American Clinical Laboratory Association (ACLA) today recognized National Kidney Month this March as a time to increase education and awareness around this oftentimes debilitating condition.
In 2005, chronic kidney disease cost Medicare $59.8 billion, 18% of Medicare spending at the time, with rapid growth projected. For the patients and families affected by CKD, a 2004 study found that the costs of care for patients with CKD were roughly double those of patients who did not suffer from the disease, $18,000 vs. $9,800. In addition, the costs of complications and related disorders like diabetes drove costs even higher, valuing at almost $36,000, more than three times the price tag of those who caught and controlled the disease early.
“From identifying the early warning signs to slowing and even preventing the cascading complications of kidney function decline, lab testing is critical at every stage of chronic disease management to ensure that all Americans receive important, life-saving results,” said Mertz.
For more information on the role and value of lab testing in treating and preventing diseases like CKD, diabetes, and heart disease, please visit acla.com.
The ACLA is a not-for-profit association representing the nation’s leading national and regional clinical laboratories on key issues of common concern, including federal and state government reimbursement and regulatory policies.